Survodutide Dosage Calculator & Research Doses

1Set Up Your Mix

10 mg/mL · 10000 mcg/mL

1. Pick your peptide

2. How much peptide is in the vial? It's printed on the label — usually something like 5 mg

3. How much water are you adding? More water makes each dose easier to measure

4. How much do you want per dose?

All answers assume a standard 1 mL U-100 syringe, where 1 unit = 0.01 mL. That is the usual insulin syringe and the one every number here is based on.

Your Answer — SurvodutideYour Answer

—

24Draw To This Line

0.24That's This Many mL

4Doses In The Vial

10 mg ÷ 1 mL = 10 mg/mL → 2.4 mg ÷ 10 mg/mL = 0.24 mL → × 100 = 24 units—

Looks good. Draw to 24 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 4 doses.

2Week-By-Week Plan — Survodutide

Phase 2 escalation

When	Dose	How Often	How Many mL	Draw To	Number Of Doses
Initiation	0.6 mg	once weekly	0.06 mL	6 u	16 doses
Step	2.4 mg	once weekly	0.24 mL	24 u	4 doses
Step	3.6 mg	once weekly	0.36 mL	36 u	2 doses
Trial max	6 mg	once weekly	0.6 mL	60 u	1 doses

Weeks until the top dose

16 weeks

Peptide used getting there

31.2 mg

Vials you'll need

4 × 10 mg

Once you're at the top dose

24 mg / 4 wk · 2.4 vials

Where this plan came from

A clinical trial schedule

Where this came from: Lancet Diabetes & Endocrinology phase 2 programme. The phase 2 programme tested both rapid and gradual escalation arms; the steps below follow a four-week cadence toward the 6.0 mg arm.

3Common Doses — Survodutide

worked out for your mix

Level	Dose	How Often	How Many mL	Draw To	Doses In Vial
Weeks 1–4	0.6 mg	once weekly	0.06 mL	6 u	4	2.4 mg
Weeks 5–8	1.2 mg	once weekly	0.12 mL	12 u	4	4.8 mg
Weeks 9–12	2.4 mg	once weekly	0.24 mL	24 u	4	9.6 mg
Weeks 13–16	3.6 mg	once weekly	0.36 mL	36 u	4	14.4 mg
Week 17 onward per 4 weeks from here on	6 mg	once weekly	0.6 mL	60 u	4	24 mg

Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About SurvodutideAbout This Peptide

Metabolic / Incretin

Also known as

BI 456906, GLP-1/glucagon dual agonist

Class

Metabolic / Incretin

Route

Subcutaneous

Half-life

~6 days

Evidence tier

Clinical

A dual GLP-1/glucagon receptor agonist in phase 3, with notable phase 2 results in MASH as well as obesity.

Buy Survodutidethis peptide

Opens optimal-pep.com in a new tab

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published

Survodutide for the treatment of obesity — phase 2 randomised trial le Roux CW, et al. The Lancet Diabetes & Endocrinology, 2024

Source of the 0.6–6.0 mg escalation arms.

Find on PubMed ↗

Survodutide in metabolic dysfunction-associated steatohepatitis Sanyal AJ, et al. New England Journal of Medicine, 2024

MASH endpoint data at the same dose range.

Find on PubMed ↗

Newest Studies — —

—

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

Research Use Only — Confirm to Continue

Survodutide Dosage & Reconstitution

1Set Up Your Mix

Your Answer — SurvodutideYour Answer

2Week-By-Week Plan — Survodutide

3Common Doses — Survodutide

About SurvodutideAbout This Peptide

Where These Numbers Come From

Newest Studies — —

More peptides

Cagrilintide

Mazdutide

All 71 peptides